Dr. Dongyang Liu is now a professor & director of Clinical Pharmacology and Pharmacometrics Office (CPPO), and deputy director of Drug Clinical Trial Center of Peking University Third Hospital (PUTH). Up to now, he was responsible for clinical trials or MiDD studies of more than 50 novel drugs as PI and published more than 60 international peered articles, such as Acta pharmaceutica Sinica B, EClinicalMedicine, Clin Pharmacokinet, Clin Infect Dis, as the first or corresponding author (citation>3000). He was invited to be the vice chairman of committeeman of Professional Committee of Pharmacometrics, and committeeman of Professional Clinical Pharmacology in Chinese Pharmacological Society as well as Associate Editor of BDD and Editor of JPKPD journal. He earned National Innovation Competition Award (Rank Six). Currently, he is majorly interested in 1) early phase clinical development for new drugs, 2) PBPK-PD-Disease model research for New drug development and precision dosing.

研究员，博士生导师，北医三院药物临床试验机构副主任，兼任其临床药理与定量药理研究室负责人、北京市心血管受体研究重点实验室副主任、北医三院-新领先改良型新药智慧开发联合研发中心主任。他作为主要研究者共负责50多个1类创新药的早期临床开发或模型引导的临床开发项目（如多格列艾汀片、KN035、加格列净等），针对特定人群（孕妇、儿童、老年人和肾损人群）和特定疾病（内分泌代谢、心血管、靶向递送肿瘤等）探索定量药理学引导的精准用药和新药加速开发，以第一或通讯作者在Lancet: EClinicalMedicine、Acta pharmaceutica Sinica B、Clin Infect Dis、Clin Pharmacokinet等杂志发表SCI文章60余篇（引用>3000次）。目前被聘为中国药理学会定量药理委员会副主任委员兼青年主委、国家药监局新药审评专家、BDD杂志副主编、JPKPD编委等职位，获得全国创新争先奖（排名第六）等奖励，主要进行临床药理学与定量药理学研究，研究方向包括：1）口服吸收PBPK模型研究；2）PBPK-PD-Disease模型引导的新药开发与精准用药研究；3）创新药临床早期开发与晚期临床药理学研究。